ALL treatment for adolescents and young adults
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Philadelphia chromosome-negative ALL (a specific type of leukemia).
- You should be between 18 and 50 years old.
- You can have had some prior treatments like steroids or one round of chemotherapy.
- Your liver function (measured by bilirubin) must be within normal limits.
- You need to agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.